Safety of Dietary Undenatured Type II Collagen: A Pilot Open-Label Overdose Clinical Investigation
デジタルデータあり
すぐに読む
CiNii Research
全国の図書館の所蔵
国立国会図書館サーチが連携している各図書館等から取得した所蔵情報を表示します。
所蔵館、利用可否等の詳細・最新状況は情報提供元の各館のサイト・データベースで直接ご確認ください。所蔵館から取寄せることが可能かなど、資料の利用方法は、ご自身が利用されるお近くの図書館へご相談ください。詳細は ヘルプ をご覧ください。
書誌情報
この資料の詳細や典拠（同じ主題の資料を指すキーワード、著者名）等を確認できます。
- 資料種別
- 記事
- タイトル
- 著者標目
- 出版年月日等
- 2022-03-04
- 出版年（W3CDTF）
- 2022-03-04
- タイトル（掲載誌）
- Functional Foods in Health and Disease
- 巻号年月日等（掲載誌）
- 12
- 掲載巻
- 12
- 掲載ページ
- 103-
- 掲載年月日（W3CDTF）
- 2022-03-04
- ISSN（掲載誌）
- 23787007
- 出版事項（掲載誌）
- Functional Food Center
- 対象利用者
- 一般
- DOI
- 10.31989/ffhd.v12i3.897
- オンライン閲覧公開範囲
- インターネット公開
- 異版
- Safety of dietary undenatured type II collagen: a pilot open-label overdose clinical investigation
- 連携機関・データベース
- 国立情報学研究所 : CiNii Research
- 提供元機関・データベース
- 学術機関リポジトリデータベース
- 要約等
- <p>Background: In advancing age population worldwide, joint discomfort and poor locomotive functions are symptoms, which are often detected. Aggravation of such symptoms potentially develops into osteoarthritis (OA) as characterized by the loss of articular cartilage in the joints of the hand, spine, knee, foot, and hip. For joint health complications, selected functional foods are frequently supplemented orally to alleviate such symptoms. In Japan, Foods with Function Claims (FFC) regulatory system is now positioned within the framework of "so-called health foods"allowing to make functional claims such as brain health and weight control claims. Moreover, a wide variety of knee joint care FFC products are presently available in the marketplace and have attracted much attention of the elderly people, expecting improvements in joint locomotive functions such as walking, sitting, standing, and climbing the stairs for the quality of life (QOL). Supplementation of undenatured type II collagen powder (NEXT-II®) in hard capsules has been clinically proven to improve such joint functions fulfilling part of the FFC rigorous guidelines, while ensuring adequate safety as foods is a crucial prerequisite for filing FFC product dossier. Methods: Twenty-two healthy male and female volunteers (age = 20-74 years) participated in this pilot open-label overdose clinical trial over a period of 4 consecutive weeks. All subjects were also monitored and assessed additional 2 weeks after the completion of the NEXT-II® supplementation period as washout or supplement-free period. Subjects took a 10-fold (10-X) dose of NEXT-II® (400 mg NEXT-II/day containing 32 mg of undenatured type II collagen/day). Daily recommended dose of NEXT-II® is 40 mg/day (containing 3.2 mg of undenatured type II collagen/day) after breakfast. Physical health examination, hematological analysis, blood, biochemistry examination, and urinalysis were performed. All subjects completed the supplementation of NEXT-II® for 4 weeks and had additional 2 weeks of washout or supplement-free period. All subjects recorded daily diaries. Results: Results demonstrated no significant differences at 0 week (baseline), 2 weeks, and 4 weeks of NEXT-II® supplementation. Furthermore, no significant differences were observed even after 2 weeks of the washout period. No adverse events were observed. Conclusions: Supplementation of 10-fold dose of NEXT-II® to the volunteers was well-tolerated and exhibited the broad-spectrum safety without observing any adverse effects in healthy Japanese subjects.</p>
- DOI
- 10.31989/ffhd.v12i3.897
- 異版（DOI）
- 10.31989/ffhd.v12i3.897
- 連携機関・データベース
- 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）
- 提供元機関・データベース
- 帝京大学 : 帝京大学研究・教育リポジトリ